NCR3

NCR3 Full Name

natural cytotoxicity triggering receptor 3

NCR3 Introduction

NCR3 encodes NKp30, one of the natural cytotoxicity receptors expressed on natural killer (NK) cells that enable these innate lymphocytes to recognize and destroy tumor cells and infected cells. NKp30 is a type I transmembrane glycoprotein of the immunoglobulin superfamily whose extracellular domain engages ligands displayed on the surface of target cells; engagement then delivers activating signals into the NK cell, triggering the release of cytotoxic granules and the production of cytokines such as TNF-alpha and interferon-gamma. The best-characterized ligand of NKp30 is B7-H6, a B7-family molecule that is absent from most healthy tissues but is induced on a wide range of tumor cells, providing a molecular explanation for why NK cells can selectively attack malignant cells. NKp30 also participates in the bidirectional crosstalk between NK cells and dendritic cells, influencing the maturation of dendritic cells and the quality of the ensuing adaptive immune response. Clinical studies have shown that the expression level of NKp30 and the presence of particular splice-variant isoforms predict the survival of patients with certain cancers, and soluble NKp30 released into the blood has been proposed as a prognostic biomarker. Because NKp30 sits at the interface of innate tumor surveillance and adaptive immunity, it has become an attractive target for immunotherapeutic strategies aimed at restoring or amplifying NK cell activity.

Figure 1. The structure of NCR3.

Receptor Structure, Signaling, and Ligand Recognition
NKp30 is encoded by the NCR3 gene, which lies within the major histocompatibility complex class III region on human chromosome 6, a genomic neighborhood rich in immune-related genes.
The receptor is a type I transmembrane protein of the immunoglobulin superfamily, containing a single extracellular immunoglobulin-like domain that mediates ligand binding.
Because NKp30 lacks intrinsic signaling motifs, it transmits activating signals by associating non-covalently with immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor proteins, principally the Fc receptor gamma chain, and in some contexts CD3 zeta.
Ligand engagement triggers tyrosine phosphorylation of the adaptor ITAMs, recruitment of Syk family kinases, and downstream activation of pathways that culminate in degranulation and cytokine production.
The principal cellular ligand B7-H6 is a member of the B7 costimulatory family whose expression on normal tissues is minimal but which is upregulated on many tumor cells, including those of hematologic and solid malignancies.
Alternative splicing of NCR3 generates isoforms, NKp30a, NKp30b, and NKp30c, which differ in their signaling capacities and exert distinct, even opposing, functional outcomes.
Soluble forms of NKp30 are produced through proteolytic shedding and can neutralize the membrane receptor or modulate immune responses when present at high levels in serum.

Tumor Surveillance, NK-Dendritic Cell Crosstalk, and Clinical Significance
The NKp30-B7-H6 axis is a key component of natural killer cell-mediated tumor surveillance: many cancer cells are killed by NK cells precisely because they display B7-H6 and therefore trigger NKp30-dependent cytotoxicity.
NKp30 also shapes adaptive immunity through its effects on dendritic cells, promoting their maturation and their ability to prime T-cell responses, a function that links innate recognition of tumors to the generation of antitumor immunity.
The balance of NKp30 splice isoforms is clinically meaningful: expression of the immunosuppressive NKp30c variant has been associated with worse outcomes in gastrointestinal stromal tumors and other cancers, whereas the activating NKp30a isoform is linked to more effective antitumor responses.
Elevated levels of soluble NKp30 in the serum of cancer patients have been correlated with reduced NK cell function and poorer survival, supporting the use of soluble NKp30 as a non-invasive prognostic biomarker.
In chronic viral infections, NCR3 polymorphisms have been associated with the efficiency of NK cell control of HIV and hepatitis C virus, underscoring the broader relevance of the receptor to infectious disease.
Immunotherapeutic strategies under investigation aim to block the immunosuppressive NKp30c pathway, to enhance NKp30-dependent killing through antibodies that cluster the receptor, or to combine NKp30 engagement with checkpoint inhibition to strengthen antitumor immunity.

Alternate Names for NCR3

NCR3; natural cytotoxicity triggering receptor 3; LY117, lymphocyte antigen 117; 1C7; CD337; NKp30; NK-p30; lymphocyte antigen 117; activating NK-A1 receptor; activating natural killer receptor p30; natural killer cell p30-related protein; MALS; LY117;